Episode 11. ASH22 Recap: Lymphoma and CLL
Blood Cancer Talks
00:00
The End of Watch and Wait for Follicle Lymphoma
The watch and wait trial presented by Michael Northend was 12 and a half years of followup for 460 patients with asymptomatic low tumor burden grade 1 to 3a follicular lymphoma. Now the authors of this study concluded that early treatment with retuximab should now be considered a standard option for patients with FL. Some influential hematologist on twitter said that this might or suggested that this might spell the end of watch and wait for follicular lymphomas I wonder what your interpretation of this starter is like.
Transcript
Play full episode
